

Monthly Market Commentary

July was a good month for global equities, particularly US large capitalisation stocks which set record highs. A generally good start to reporting season helped. Additionally, greater clarity on US tariffs, and the passing of the 'One Big Beautiful Bill Act' buoyed risk-on sentiment.

Investors appeared unconcerned that US consumers are facing the highest tariff regime since the 1930s at the same time as US government finances are set to become even more stretched. According to the Congressional Budget Office, the US federal deficit is expected to remain at an elevated level of around 6% of GDP over the next decade. Over the same period, the July enacted 'One Big Beautiful Bill' is estimated to add approximately USD\$4.1 trillion to the deficit, potentially pushing it to over 7% of GDP.

As noted, US markets were strong in July with the NASDAQ and S&P500 up 3.7% and 2.17%, respectively. In contrast, small caps lagged with the S&P600 Small Cap Index up only 0.9%. In local currency terms, overseas bourses also did well with the UK FTSE up 4.2%, well ahead of France's CAC and Germany's DAX which rose 1.4% and 0.7%, respectively. In Asia, China's Shanghai Composite Index was up 3.7%, with Japan's Nikkei225 also up 1.4%. Given broad-based US optimism and the accompanying strength of the USD in July (DXY Index +3.1%), overseas bourse returns were lower in USD terms.

Information Technology was the standout performer on a sector basis, up 4.1%, with Energy and Utilities also delivering solid performance, up 2.4% and 2.2%, respectively. At the other end of the spectrum, Health Care fell 3.1% thanks to more weakness in US managed care stocks (further downgrades thanks to rising medical costs) and significant share price falls in some high profile GLP-1 makers. Most notably, Novo Nordisk's share price fell ~23% after downgrading FY25 EBIT growth to 10-16% (vs previous guidance of 16-24% growth) - a reminder that investors can still lose money even as profits grow.

Against this backdrop the Fund returned +0.51% for the month.

The Australian dollar fell 2.4% against the USD in July. Commodities were modestly lower with the Bloomberg Commodity Index down 0.8%, despite a 6.4% rise in WTI oil prices. VIX remained largely unchanged during the month at around 16.7, with yields on US 10yr Treasuries rising 15bps to close at 4.37%.

Pharmaceutical giant, Johnson & Johnson was the biggest contributor to Fund performance in July, bucking the broader trend in Health Care weakness. Its shares rose strongly after a solid Q2 result where the company raised FY25 sales and EPS guidance and signalled positive momentum into 2026 with potential upside to long-term targets. With the stock trading on a ~15x P/E, it still offers compelling value, and we will continue holding.

Goldminer Newmont was also a meaningful contributor to the Fund's performance. Its shares rose after a strong Q2 result characterised by good cost management, conservative FY25 production guidance and more cash returns to shareholders via a new USD\$3bn buyback. Having divested most non-core assets, Newmont now owns some of the most attractive gold mines globally (longest-life/lowest-cost). It also enjoys considerable balance sheet optionality (Net Debt/EBITDA ~0.1x) meaning it can still fund even more capital management initiatives. Hence, with the stock trading on a ~8% FCF yield (based on spot gold prices) there remains significant upside for shareholders from here.

Swedish health and hygiene group, Essity was the Fund's biggest detractor. The shares fell after it missed Q2 earnings estimates by ~5% thanks to weaker-than-expected volumes, FX headwinds and higher cost of goods sold. The company also flagged higher investments as it looks to re-ignite volume growth. The good news is that a solid balance sheet affords management time to execute an uptick in volumes, and with the stock trading near-trough sales multiples we think the skew is to the upside (~30% upside to where we see fair value).

We believe the most compelling way to compound clients' wealth is by utilising multiple return sources to deliver superior risk-adjusted investment outcomes.

- Long-term compounding of investor wealth
- Multiple sources of return
- Quarterly distributions
- Risk focused investment mindset



The investment process behind the Talaria Global Equity Fund takes a high conviction, value biased approach to construct a portfolio of high quality, large cap companies from around the globe. Our unique investment methodology harnesses the benefits of consistent income generation and capital appreciation to grow investors' real wealth.

Performance as at 31 July 2025¹

	1 Month	3 Months	6 Months	1 Year	3 Years (pa)	5 Years (pa)	7 Years (pa)	10 Years (pa)	Since Inception (pa) ²
Total Return	0.51%	0.67%	1.04%	5.20%	8.89%	10.52%	7.74%	6.73%	7.54%
Avg. Market Exposure ⁴	58%	58%	61%	64%	59%	58%	58%	59%	61%

¹ Fund Returns are calculated after fees and expenses and assume the reinvestment of distributions.
² Inception date for performance calculation is 1 October 2005.
³ Past performance is not a reliable indicator of future performance.


⁴ Average Market Exposure calculated on delta-adjusted exposure of underlying portfolio. Since inception market exposure is calculated from 1 October 2005.

Growth of \$100,000 Since Inception⁵



⁵ Calculations are based on exit price, net of management fees and expenses and assumes reinvestment of distributions Past performance is not a reliable indicator of future performance.

Annual Distributions⁶




⁶ Illustrates Distribution Returns for the Talaria Global Equity Fund - Foundation Units for the financial year ending 30 June 2025. Inception date is 1 October 2005.

Top 10 Holdings⁷

Company Name	Holding	Country	Sector	Description
Newmont	5.5%	USA	Materials	One of the top 3 gold producers in the world
Roche	4.8%	Switzerland	Health Care	A global leader in cancer treatments
Sanofi	4.7%	France	Health Care	Top 5 pharmaceutical firm with leading positions in diabetes and rare diseases
Everest Re	4.5%	USA	Financials	Leading global provider of reinsurance and insurance services
Johnson & Johnson	4.2%	USA	Health Care	Pharmaceutical, medical devices and consumer health products company
Essity	3.6%	Sweden	Consumer Staples	A global health and hygiene company based in Sweden
Bunzl	3.5%	United Kingdom	Industrials	Multinational distribution and outsourcing business
Chubb	3.5%	USA	Financials	Global Property & casualty insurance company
Bayer	3.4%	Germany	Health Care	Multinational pharmaceutical and life sciences company
CF Industries	3.2%	USA	Materials	North America's largest manufacturer of nitrogen-based fertiliser


⁷ Weightings include option positions held and cash backing put options. It assumes that put options will be exercised. Should the put option not be exercised the cash will revert to the unencumbered cash portfolio or may be used to cover further put options.

Sector Allocation⁸



^{8,9} Weightings include option positions held and cash backing put options. It assumes that put options will be exercised. Should the put option not be exercised the cash will revert to the unencumbered cash portfolio or may be used to cover further put options.

Regional Allocation⁹



* USA includes American Depositary Receipts (ADRs) listings.

Fund Snapshot

Management Fee	Nil	Inception Date	1 October 2005
Performance Fee	20% - subject to High Watermark	Liquidity	Daily
Distributions	Quarterly	Availability	Wholesale Clients Only
Minimum Investment	\$50,000	Buy / Sell Spread	0.20% / 0.20%

Important Information

Equity Trustees Limited ("Equity Trustees") (ABN 46 004 031 298), AFSL 240975, is the Responsible Entity for the Talaria Global Equity Fund - Foundation Units. ("the Fund"). Equity Trustees is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a publicly listed company on the Australian Securities Exchange (ASX: EQT). Foundation Units are currently available to what the Corporations Act 2001 (Sections 761GA and 761G) defines as Wholesale Clients. Talaria Asset Management Pty Ltd ABN 67 130 534 342, AFS Licence No. 333732 is the investment manager and distributor of the Fund. References to "we" means Talaria Asset Management Pty Ltd, the investment manager. The information in this document is general information only and is not based on the financial objectives, situation or needs of any particular investor. In deciding whether to acquire, hold or dispose of the product you should obtain a copy of the current Information Memorandum and consider whether the product is appropriate for you. A copy of the Information Memorandum can be obtained by calling Talaria Asset Management on (03) 8676 0667. Investment decisions should not be made upon the basis of the Fund's past performance or distribution rate, or any ratings given by a rating agency, since each of these can vary. In addition, ratings need to be understood in the context of the full report issued by the rating agency itself. The information provided in the document is current at the time of publication. The Zenith Investment Partners (ABN 27 103 152 672, AFS Licence 226872) ("Zenith") rating (assigned November 2024 for fund AUS0035AU) referred to in this piece is limited to "General Advice" (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at Fund Research Regulatory Guidelines. The rating issued 04/2025 is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit lonsec.com.au for ratings information and to access the full report. © 2025 Lonsec. All rights reserved. The Genium rating (assigned May 2025) presented in this document is issued by Genium Investment Partners Pty Ltd ABN 13 165 099 785, which is a Corporate Authorised Representative of Genium Advisory Services Pty Ltd ABN 94 304 403 582, AFSL 246580. The Rating is limited to "General Advice" (s766B Corporations Act 2001 (Cth)) and has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without notice. Past performance information is for illustrative purposes only and is not indicative of future performance. It is not a recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision in relation to this financial product(s). Genium receives a fee from the Fund Manager for researching and rating the product(s). Visit genium.com.au for information regarding Genium's Ratings methodology. The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of MSCI Inc. ("MSCI") and Standard & Poor's, a division of The McGraw-Hill Companies, Inc. ("S&P") and is licensed for use by Talaria Asset Management. Neither MSCI, S&P nor any third party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability and fitness for a particular purpose with respect to any of such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

Signatory of:



Principles for Responsible Investment